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Abstract: Pharmacophore modeling is a successful yet very diverse subfield of computer-aided 
drug design. The concept of the pharmacophore has been widely applied to the rational design 
of novel drugs. In this paper, we review the computational implementation of this concept and 
its common usage in the drug discovery process. Pharmacophores can be used to represent 
and identify molecules on a 2D or 3D level by schematically depicting the key elements of 
molecular recognition. The most common application of pharmacophores is virtual screen-
ing, and different strategies are possible depending on the prior knowledge. However, the 
pharmacophore concept is also useful for ADME-tox modeling, side effect, and off-target 
prediction as well as target identification. Furthermore, pharmacophores are often combined 
with molecular docking simulations to improve virtual screening. We conclude this review 
by summarizing the new areas where significant progress may be expected through the 
application of pharmacophore modeling; these include protein–protein interaction inhibitors 
and protein design.
Keywords: ADME-tox, computer-aided drug design, pharmacophore fingerprint, protein 
design, virtual screening
What is computer-aided drug design?
Drug design is an expensive and laborious process of developing new medicine. 
This process has its origin in herbal remedies dating back millennia.1 Only since 
the last century have drugs had a (semi)synthetic origin.2 The first hit compounds 
often lack both potency and safety, and must therefore be optimized. While histori-
cally this was a trial-and-error process,3,4 soon rational strategies were developed 
to improve potency.5,6 As with any data handling procedures, computers have 
become a more prominent and ubiquitous tool in drug discovery since the 1980s.7 
The crossover between computational and pharmaceutical research is typically 
designated computer-aided drug design (CADD).8,9
CADD covers a broad range of applications spanning the drug discovery pipeline, 
although these are highly clustered in the early phases. The main purpose of CADD 
is to speed up and rationalize the drug design process while reducing costs.10 The aim 
of the earliest phase in drug discovery is to identify the first hit compounds, which 
is sometimes attempted by high-throughput screening (HTS), the testing of many 
thousands of compounds with a suitable activity assay. The in silico counterpart of in 
vitro HTS is referred to as virtual screening and aims at filtering libraries of molecules 
using computational methods to prioritize those most likely to be active for a given 
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target.11 Later in the drug discovery pipeline the potency of 
the hit and lead compounds needs to be improved.12 New 
derivatives are designed with or without a different scaffold 
at the core of the molecule.13 The ultimate goal is to design 
highly potent and specific molecules which also have a suit-
able intellectual property position.14 This can be achieved 
by classical medicinal chemistry approaches, where the 
design can be based on the observed structure–activity 
relationships (SAR) or based on structural information.15 
Computational methods however can also be used to create 
diverse derivatives based on different scaffolds,16,17 and then 
score them for improved potency. This prioritizes the most 
promising derivatives from a very wide chemical space 
in a relatively short time.18,19 However, the potency of the 
compounds is not the only consideration. Pharmacokinetic 
properties (absorption, distribution, metabolism, excretion) 
and toxicity, referred to as ADME-tox, are also of vital 
importance if a compound is to be clinically useful.20–22 
As well as a battery of in vitro and in vivo experiments, 
virtual methods have also been developed to predict the 
ADME-tox profile of drug-like compounds early during 
the development process.
The basis of all CADD methods is chemo-informatics, 
the application of data storage, handling, and retrieval 
methods to chemical structures, their properties, and 
biological activity.23,24 Chemo-informatics also covers 
the calculation of molecular descriptors that describe a 
chemical or physical property based on the molecules’ 
structure, and which can be used for filtering compounds.25 
In order to be able to compare and quantify (dis)similarity 
between molecules, molecular fingerprints are often the 
methods of choice.26
Another very important CADD subfield focuses on 
quantitative structure activity/property relationship (QSAR/
QSPR), in which the physicochemical properties (as cal-
culated by molecular descriptors) of a set of inhibitors are 
related to the inhibitory activity or toxicity to construct a 
predictive model for novel inhibitors.27–29 QSAR has become 
a very popular tool to profile novel inhibitors accurately in 
silico without going through expensive and time-consuming 
in vitro and in vivo assays.30
Probably the best known and most used CADD method 
is molecular docking simulations, whereby the 3D binding 
mode of a given ligand for a given biomolecular receptor 
(typically a protein structure) is predicted and scored for 
affinity. This is extremely useful for the structural analysis 
of protein–ligand interactions where experimental structural 
information is absent.31 Docking, however, has also become 
a very popular tool to screen for hit compounds virtually, or 
by reverse engineering to identify the target.32–35
The CADD methods briefly introduced earlier are some 
of the most widely known, but many more exist including 
artificial-intelligence-based methods.36,37 The topic of this 
review, however, is another very successful CADD method 
known as pharmacophore modeling.38–42 This review is 
aimed at medicinal chemists and others new to CADD 
and covers the history, progress, and current limitations 
of pharmacophore modeling. We do not list or compare 
the many different pharmacophore modeling programs or 
algorithms.
What is a pharmacophore?
Historical perspective
The original concept of the pharmacophore was developed 
by Paul Ehrlich during the late 1800s.43 At that time, the 
understanding was that certain “chemical groups” or func-
tions in a molecule were responsible for a biological effect, 
and molecules with similar effect had similar functions 
in common. The word pharmacophore was coined much 
later, by Schueler in his 1960 book Chemobiodynamics and 
Drug Design, and was defined as “a molecular framework 
that carries (phoros) the essential features responsible for a 
drug’s (pharmacon) biological activity.”44 The definition of 
a pharmacophore was therefore no longer concerned with 
“chemical groups” but “patterns of abstract features.”
Since 1997, a pharmacophore has been defined by the 
International Union of Pure and Applied Chemistry as:
A pharmacophore is the ensemble of steric and electronic 
features that is necessary to ensure the optimal supramo-
lecular interactions with a specific biological target and to 
trigger (or block) its biological response.45
The pharmacophore should be considered as the largest com-
mon denominator of the molecular interaction features shared 
by a set of active molecules. Thus a pharmacophore does not 
represent a real molecule or a set of chemical groups, but is 
an abstract concept. Despite this clear definition, the term 
pharmacophore is often misused by many in medicinal chem-
istry to describe simple yet essential chemical functionalities 
in a molecule (such as guanidine or sulfonamides), or com-
mon chemical scaffolds (such as flavones or prostaglandins). 
Often the long definition is simplified to “A pharmacophore 
is the pattern of features of a molecule that is responsible for 
a biological effect,” which captures the essential notion that 
a pharmacophore is built from features rather than defined 
chemical groups.
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Pharmacophore concepts in CADD
While the pharmacophore concept predates any form of 
electronic computer, it has nevertheless become an impor-
tant tool in CADD. Every type of atom or group in a mol-
ecule that exhibits certain properties related to molecular 
recognition can be reduced to a pharmacophore feature. 
These molecular patterns can be labeled as hydrogen 
bond donors or acceptors, cationic, anionic, aromatic, or 
hydrophobic, and any possible combinations.46 Different 
molecules can be compared at the pharmacophore level; this 
usage is often described as “pharmacophore fingerprints.” 
When only a few pharmacophore features are considered 
in a 3D model the pharmacophore is sometimes described 
as a “query.”
Pharmacophore fingerprint
While molecules are 3D entities, the pharmacophore rep-
resentation reduces a molecule to a collection of features 
at the 2D or 3D level.47,48 A pharmacophore fingerprint 
is an extension of this concept, and typically annotates a 
molecule as a unique data string. All possible three-point 
or four-point sets of pharmacophore features (points) 
are enumerated for each ligand.49 The distance between 
the feature points is counted in bonds (for  topological 
fingerprints), or by distance-binning when using 3D fin-
gerprints (Figure 1). The resulting fingerprint is a string 
describing the frequency of every possible combination at 
predefined positions within the string. Several variants of 
pharmacophore fingerprints have been designed and are 
frequently used.
Such a fingerprint can be used to analyze the  similarity 
between molecules or among a library of molecules. 
Alternatively, a fingerprint model can be used to analyze 
the common elements of active ligands to identify the key 
contributing features to the biological function.
Pharmacophore model or query
A pharmacophore model consists of a few features organized 
in a specific 3D pattern.50 Each feature is typically represented 
as a sphere (although variants exist) with a radius determin-
ing the tolerance on the deviation from the exact position 
( Figure 2). The features can be labeled as a single feature 
or any logic combination consisting of “AND,” “OR,” and 
“NOT” to combine different interaction patterns within one 
label. Additional features can describe forbidden volume 
interactions (typically to represent the receptor boundary).
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Figure 1 Pharmacophore fingerprints.
Notes: A pharmacophore fingerprint is the representation of a small molecule ligand (A) annotated with molecular interaction features (B) into a string. Typically, every possible 
three- (or four-) point combination of molecular interaction features (C), with different distances between the features, calculated either through space or by the number of bond 
lengths (D), is calculated and the frequency of occurrence is stored in a string (E). Such strings are useful for the easy comparison of similarity between multiple molecules.
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Such pharmacophore features are typically used as 
queries to screen small molecule libraries of compounds.51 
In these libraries all the compounds are present in their 
low-energy biorelevant conformations. Each of these con-
formations is fitted to the pharmacophore query by aligning 
the pharmacophore features of the molecule and the query 
is composed. If a molecule can be fitted inside the spheres 
representing the query features it is considered a hit molecule. 
Often the pharmacophore query can be too complex to find 
hit molecules from a given library, and partial matching may 
be allowed. In such cases only certain features considered 
essential for activity are matched. Additional uses of such 
models are to align molecules or facilitate molecular dock-
ing simulations.52–54
Depending on the situation and the type of experiment, 
multiple strategies are available to construct pharmacophore 
models, either manually or using automated algorithms, and 
this is discussed in the next chapter.
Pharmacophore modeling in virtual 
screening
Pharmacophore modeling is most often applied to virtual 
screening in order to identify molecules triggering the 
desired biological effect. For this purpose, researchers create 
a pharmacophore model (query) that most likely encodes the 
correct 3D organization of the required interaction  pattern. 
Depending on how much is known about the particular 
 protein target, different options are available to construct 
such a query (Figure 3).
In general, it is good practice to divide the ligand data 
into two sets, a training and an evaluation set to validate 
the generated pharmacophore query, when multiple active 
ligands (and inactive derivatives) are known.55
H-bond acceptor
H-bond donor
Cationic
Hydrophobic
Aromatic
Anionic
Figure 2 Pharmacophore query.
Notes: A pharmacophore query is comprised of different features. The features represent molecular recognition motifs such as hydrogen bond acceptors or donors, anionic, 
cationic, hydrophobic, and aromatic groups. The radius of the sphere determines the strictness of the geometric constraint. For features where the correct orientation 
of the interaction is important such as hydrogen bonds and the aromatic plane, a second feature can be used indicating the vector of the interaction (or the normal of the 
plane). A pharmacophore query can combine any of these features, with different radii and logic operations such as “AND,” “OR,” and “NOT.” On the left a hypothetical 
pharmacophore query for BRAF kinase is given.
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Figure 3 Four different situations for the pharmacophore search.
Notes: The figure shows the four different situations that may be encountered when 
starting a virtual screening. The situations include the absence of both the ligand and 
protein structure information, where except for divination, experimental screening is 
the only option. The second option is the presence of active ligands, but the protein 
structure is unknown, where pharmacophores can be used for ligand-based virtual 
screening. The best situation is when binding ligand and structural information is 
present. The most challenging option is when only a protein structure is available.
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While in all these cases pharmacophore queries are 
considered positive filters to identify compounds, they may 
in fact also be used as negative filters to avoid side effects 
as well.56,57
No protein structure and no ligand structure  
is known
If the target structure and all its ligands are unknown, pharma-
cophore modeling is impossible. The only option to employ 
the pharmacophore principle would be to design a diverse 
library employing a diversity metric based on pharmacophore 
fingerprints to ensure optimal diversity of the library, contain-
ing a wide variety of molecules with different pharmacophore 
feature composition. Indeed, considering the large number 
of available and potential compounds, the trend is to design 
libraries very carefully in order to cover chemical space 
efficiently in any search process.47,48,58,59
No protein structure, but active ligand structures  
are known
The other scenario is that the structure of the receptor (and 
any complex with the ligand) is unknown. This is frequently 
the case in drug discovery. If only a single active molecule 
is known, then it is impossible to map the key contributing 
pharmacophore features onto the molecule, and the only 
option may be to use similarity searches (such as using phar-
macophore fingerprints) to retrieve similar molecules.60 Once 
these have been tested, a set of multiple active and inactive 
compounds may be known and more advanced pharmacoph-
ore modeling can be utilized.
When a set of active ligands of known structure, with sim-
ilar or different scaffolds, is available, then it is possible to use 
ligand-based pharmacophore modeling.52,61 The  elucidation 
of the putative pharmacophore involves two steps. First, 
the conformational space of the flexible molecules needs to 
be covered extensively since the bioactive conformations are 
unknown. Second, the molecules need to be aligned by com-
mon pharmacophore features, which can be retained in a 3D 
model. Using inactive derivatives, the essence of the features 
as well as the permitted steric arrangement of the ligands 
can be mapped as well. The Catalyst-HypoGen algorithm 
in particular stands out from the variety of tools available 
for this purpose.62 This is a combination of QSAR and the 
pharmacophore method. It attempts to correlate structure 
and activity values (K
i
 or half maximal inhibitory concentra-
tion [IC
50
]) by constructing a pharmacophore model. Thus, 
HypoGen not only identifies a query compound as “active” 
or “inactive” in the traditional function of a pharmacophore 
model, but also predicts activity value based on regression 
of the training dataset.
Protein and ligand structures are known
In the third case, structural information is present for both 
ligands and the receptor protein. Usually a pharmacophore 
model represents the key features of a small molecule that 
allow it to bind to some receptor molecule, but this idea can 
be reversed and pharmacophore queries built from features 
of a protein active site.63 These features describe the principle 
interactions between the protein and its ligands, and can 
be mapped onto the bioactive conformation of the ligand. 
Ideally the structural model is derived from crystallographic 
or nuclear magnetic resonance data, but homology models or 
other structural data can be used as well. Although a struc-
ture for one ligand may be enough, it is beneficial to have 
3D information for multiple ligands to identify the common 
interactions. While this approach is compatible with the 
majority of pharmacophore modeling methods, LigandScout 
is notable as the first software package able to construct 
automatically a query from one or more Protein Data Bank 
(PDB) files based on protein–ligand interactions.64
Such structure-based pharmacophore queries have mul-
tiple applications. They can be used for virtual screening, 
ligand binding pose prediction, and comparison of binding 
sites.65
Only the protein structure is known
In the last case, structural information for the protein recep-
tor, but no active ligands, is known. In this case, a putative 
pharmacophore model can be constructed by analyzing the 
chemical properties of the binding site of interest. There 
are several different computational approaches that can 
directly convert 3D atomic structures of protein binding 
sites into queries. The interaction maps of the de novo drug 
design tool LUDI can be used to create a pharmacophore 
query.66 HS-Pharm is a knowledge-based method that uses 
machine-learning algorithms to prioritize the most interest-
ing interacting atoms and to generate an interaction map 
within the binding site.67 Subsequently, the interaction map 
is converted into pharmacophore features. The GRID pack-
age is another approach to analyze the pocket in order to 
identify the key interactions.68 Using molecular interaction 
fields, the most favorable positions of atomic probes in the 
binding site can be identified and converted into pharma-
cophore features.69 Although many successes have been 
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reported, the absence of any ligand structural information is 
a distinct disadvantage to drug design, since in the absence 
of a molecular scaffold it is hard to map the features in 3D 
space which can still be covered by atoms that are restrained 
by bond lengths and angles in the ligands.
In all of these examples, pharmacophore queries are 
utilized to identify active molecules that fulfill certain geo-
metric and chemical restraints. Because of the simple yet 
versatile character of a pharmacophore query, it can be used 
not only to identify active molecules, as suggested from the 
IUPAC (International Union of Pure and Applied Chemistry) 
definition of a pharmacophore, it can in fact also be used as 
a negative query, in order to identify molecules with undesir-
able properties.
In recent work by Voet et al, for example, a double 
pharmacophore query was utilized to identify strict human 
androgen receptor (hAR) antagonists.70 Prostate cancer 
therapy often relies on anti-androgens that antagonize the 
hAR function.71 However, resistant mutations tend to appear 
in the hAR so that the antagonists become agonists. In their 
work, the available structural information of the hAR with 
compounds in the agonist and the antagonist conformations 
were used. A pharmacophore query was generated based 
on the known antagonists in agonistic conformation, and 
remapped in 3D onto a second query in the antagonistic con-
formation. Following a combined pharmacophore screening 
method, compounds were identified that only fulfilled the 
antagonist query, but not the agonistic query. Experimental 
evaluation of the compounds confirmed the strictly antago-
nistic activity of the compounds toward both wild-type hAR 
and drug-resistant mutants.
Pharmacophore methods in docking 
simulations
As indicated in the previous section, pharmacophore models 
are very suitable as queries for virtual screening of databases. 
Nevertheless, one of the more common approaches in virtual 
screening is a so-called hierarchical approach in which differ-
ent methods are combined consecutively. This is also known 
as the funnel principle, where at each consecutive step the 
compounds most unlikely to be active are removed, leav-
ing the most promising compounds for virtual screening.72 
Typically, every step of the hierarchical approach consists 
of a more complex, computationally demanding step than 
the previous one. As such, pharmacophore models are often 
utilized as a filter to identify compounds that fulfill simple 
geometric and chemical functionality requirements of the 
query, prior to more complicated and computationally 
demanding approaches such as molecular docking.
Molecular docking simulations are computational meth-
ods that aim to predict the binding mode of a compound for a 
given receptor as well as the quality of the interaction, often 
by attempting to predict the affinity (free energy of binding) 
using a scoring function.31 Often molecular docking simula-
tions are used to screen large datasets of compounds for a 
given target, and compounds are ranked according to their 
predicted affinity. Due to the high number and diversity of 
the screening compounds, as well as the knowledge that most 
of the screened compounds are in fact probably inactive, the 
top scoring compounds are most likely inactive and better 
compounds are ranked below them. Although this ranking can 
still be better than random, typically only a few compounds 
are selected from those scoring best, and many of them often 
turn out to be inactive.73,74
Several options are available for combining docking-
based virtual screening with pharmacophore-based virtual 
screening:
•	 The database of ligands can be pre-filtered using a 
pharmacophore query, prior to evaluation using dock-
ing simulations.72
•	 The docking simulations can be post-filtered using a phar-
macophore query to remove any compounds that fail to 
bind according to the pharmacophore query. The method 
can also discard compounds that would have scored well 
in a pure pharmacophore search, but that fail to bind 
according to some hypothesis taking more information 
into account, such as incompatibility of the overall ligand 
structure with the receptor site. In such a case, the ligands 
are evaluated in absolute conformation and should not be 
allowed to align with the pharmacophore features.75
•	 Another alternative is to use the pharmacophore alignment 
to guide the placement during the docking simulations.76,77 
The pharmacophore model can in this case be used for 
the placement of the ligand, similarly to the fitting of a 
molecule into the pharmacophore query; or to guide the 
placement by using a constraint while scoring the different 
docking poses. The pharmacophore query could originate 
from a user-defined query or an automatically generated 
receptor-based pharmacophore query.53
Pharmacophore models are very useful for enriching the 
top scoring docking results with active compounds. This 
was demonstrated in the recent SAMPL4 virtual screening 
challenge where competitors were asked to rank a set of 
compounds for a given target, HIV-1 Integrase, without any 
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knowledge of activity of the compounds in the library.78 The 
top results were obtained for the group using a hierarchical 
method consisting of pharmacophore pre-filtering as well as 
pharmacophore post-filtering of the docking results.60
Applications of pharmacophores in 
ADMe-tox
Poor ADME-tox is a major contributing factor to failures 
during drug development and clinical trials.79,80 It is, there-
fore, widely accepted that the ADME-tox properties should 
be profiled early during the drug discovery process, and 
pharmacophore modeling approaches are often used for such 
ADME-tox predictions.81 The pharmacophore models can 
be used to identify possible interactions of drugs with drug-
metabolizing enzymes by matching the equivalent chemical 
groups of test molecules to those of drug molecules with a 
well-known ADME-tox profile.82
The enzymes of major importance for observed 
 ADME-tox profile are the cytochrome P450s (CYP) that 
initiate drug breakdown. It has been estimated that only 
six CYP isoenzymes (1A2, 2C9, 2C19, 2D6, 2E1, and 3A4) 
are responsible for over 90% of drug metabolism.83 Based 
on the observed interactions of known drugs with the CYP 
enzymes, receptor-based pharmacophore models have been 
generated that are able to predict the binding of a drug-like 
compound to a certain CYP and assess the possibility of 
degradation by this enzyme.84–87
Similarly, ADME-tox pharmacophore models have been 
generated for the uridine  5′-diphospho- glucuronosyltransferas
es, which are enzymes related to drug clearance, and transport-
ers such as P-glycoprotein and organic cation transporter.88,89
Pharmacophore-guided drug target 
identification
While typically the aim of CADD is to identify and optimize 
drug-like molecules for a given target, the opposite situa-
tion also exists. Often drug molecules are known, but the 
mechanism of action is unclear. These compounds are often 
derived from herbal medicine, or phenotypically developed 
drugs. In such cases, CADD may help identify the target. 
 Chemoinformatical fingerprint-based similarity tools are 
employed to identify close analogue compounds with a 
known mechanism of action.90,91 Nevertheless, pharmacoph-
ore modeling may also be an option, rather than screening 
compounds with a pharmacophore query. The molecule itself 
may become the query and the aim is to identify the most 
likely pharmacophore model that fits the molecule. Such 
 collections of pharmacophore models may be constructed 
manually or automatically generated from the PDB data-
base.64 Similarly, this approach may also be used to fish for 
a target for a given compound with a yet unknown activity.
One example of such an approach was reported by Roll-
inger et al.92 Using LigandScout, several plant metabolites 
were investigated and multiple potential drug targets were 
identified for these compounds. Experimental testing of the 
compounds for the given targets validated the applicability of 
this method. It may be expected that pharmacophore models 
will play a significant role in the future, as polypharmacol-
ogy or drug repositioning become more widespread.56,91,93 
Alternatively, this approach may also help to predict possible 
side effects or off-targets that can be taken into account to 
design more specific compounds.57
Limitations of pharmacophore 
methods
Despite the abundance of successful cases of drug design 
relying on pharmacophore modeling, as with any method, it 
is not failsafe and one should be cautious about the limita-
tions of this technique.94
The major limitation in virtual screening by pharmacoph-
ore is the absence of good scoring metrics. Whereas docking 
simulations are based on scoring functions trying to predict 
the affinity, and similarity searches utilize similarity metrics 
such as the Tanimoto score, pharmacophore queries do not 
have a reliable, general scoring metric. Most commonly, 
the quality of fitting the ligand into a pharmacophore query 
is expressed by the root mean square deviation between the 
features of the query and atoms of the molecule.55 This metric, 
however, is unable to take any similarity into account with 
known inhibitors, and also is unable to predict the overall 
compatibility with the receptor protein, and thus molecules 
that hit a pharmacophore query may be very different from 
other inhibitors and have functional groups which are not 
complementary with the receptor binding site, rendering 
them inactive despite being a perfect match.
A second limitation is the dependency of a pharmacoph-
ore-based virtual screen on a pre-computed conformation 
database. These databases only contain a limited number 
of low-energy conformations per molecule.95,96 It may be 
possible that an active molecule cannot be identified as the 
conformation is missing. This is especially the case for the 
many different conformations of rotatable bonds of small 
molecular functionalities such as hydroxyl groups. Differ-
ent rotations would be very hard to be  distinguished during 
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the  conformation generation in terms of root mean square 
 deviation differences, and thus may not be thoroughly 
sampled. Often pharmacophore search tools are able to rotate 
such bonds during the fitting process to obtain conformations 
with correct directions on the small flexible polar groups.
Finally, a major limitation is that there is no one clear 
way to construct a pharmacophore query. In many cases, 
pharmacophore models are able to retrieve molecules, but 
different models may have worked. One example is the case 
of Christ et al versus De Luca et al, where for a similar target, 
a similar yet slightly different pharmacophore was created.97,98 
While screens were performed on a similar dataset, very 
different molecules were identified. Although this is just 
one example, it is very likely that there are many more. This 
is also clear from the analysis of a wide variety of kinase 
inhibitors. In many cases, kinase inhibitors are very similar 
to each other and yet have very different activity profiles for 
the kinome. Pharmacophore approaches aimed at identifying 
kinase inhibitors would without any doubt identify kinase-
inhibitor-like molecules; nevertheless, there would not be a 
clear guarantee that these molecules would be active for the 
targeted kinase.99
In conclusion, plenty of experience and a certain dose 
of serendipity may be required for successful results. The 
influence of expert knowledge for in silico screening, also 
known as the in cerebro step, has been demonstrated during 
the virtual screening SAMPL4 challenge.60
While target identification, prediction of side effects, and 
ADME-tox profiling appear to be promising applications for 
pharmacophore modeling, success is limited for new mol-
ecule classes as information is lacking for such compounds 
or targets.100
Future perspectives on 
pharmacophore modeling
Pharmacophore modeling has been around since the begin-
ning of CADD and has evolved from a basic concept into a 
well-established CADD method with applications including 
similarity metrics, virtual screening, ligand optimization, 
scaffold hopping, target identification, and so on. Given the 
simplicity and versatility of the pharmacophore concept, it 
can be anticipated that further developments will be made 
in the future for different applications.
Fragment-based drug design
Over the last two decades, fragment-based drug design 
has become a well-established method for the rational 
 development of novel drugs.101 Rather than screening 
drug-like molecules (with molecular weights of around 
500 Da), smaller molecules with a molecular weight up to 
350 Da (referred to as fragments) are being screened for 
affinity with a receptor using highly sensitive biophysical 
methods. Fragments showing some affinity for the target are 
grown into bigger and more potent compounds, and frag-
ments binding to adjacent areas can be linked as well.
Since the diversity of small molecule fragments can 
easily be sampled with a few hundred compounds, in silico 
screening methods are highly suitable for fragment-based 
design. CADD methods such as docking and pharmacophore 
modeling have therefore also been used to identify fragment-
like compounds in silico prior to testing in vitro; subsequent 
fragment recombination can be used for the de novo design 
of inhibitors.66,102,103
In a first approach, the starting point is a single phar-
macophore query that spans two (or more) sub-pockets 
in the receptor binding site. An additional pharmacophore 
feature is added that does not represent a molecular rec-
ognition feature, but represents an atom in the fragments, 
where the two fragments of the different pockets may 
overlap and will be linked to each other.
Then fragments are identified that fulfill the features 
present in a sub-pocket of the pharmacophore query, as 
well as on the linking feature. Then the compatibility of the 
fragment hits for the respective sub-pockets is evaluated in 
terms of possibility to maintain the correct conformation 
after linking the two fragments. Subsequently the de novo 
designed compounds can be synthesized and evaluated.
In the following example, using a different yet similar 
strategy, Cavalluzzo et al designed a novel small molecule 
inhibitor binding to the LEDGF/p75 protein, based on an 
inhibitory peptide.104 They used predefined amino acid 
side chain fragments taken from the inhibitory peptide, 
and constructed a pharmacophore query to link the two 
predefined fragments with a third scaffold fragment that 
mimicked similar interactions as the peptide. All possible 
compounds were enumerated virtually, and for the com-
pounds that were able to adopt a conformation similar to 
the pharmacophore query after linking all fragments, the 
chemical synthesizability was assessed. Following synthe-
sis, the inhibitory potency of the compound was found to 
be 30 µM IC
50
 compared to 7.4 µM IC
50
 for the most potent 
inhibitory peptide.105
Even when active fragments have been identified using 
the classical in vitro methods, computational pharmacoph-
ore methods can be applied to identify novel derivatives. 
For example, pharmacophore fingerprint-based similarity 
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 searching and the generation of 3D pharmacophore  queries 
are suitable means to identify bigger and more potent 
 molecules from small molecule libraries.
Protein–protein interaction (PPI) 
inhibition
Although once thought to be undruggable, “high-hanging 
fruits on the drug discovery tree,” PPIs have drawn a great 
deal of attention in recent years.106 The undruggable image 
has disappeared and an increasing number of small molecule 
inhibitors of PPIs (SMPPII) have been reported. Most of 
the early inhibitors originate from HTS.107 Structural analy-
sis of proteins in PPI complexes and inhibitor complexes 
show that the interactions at the PPI interface are being 
mimicked by the ligand.108 SMPPII are found to copy the 
natural interaction not only in terms of shape and chemistry, 
but even at the electrostatic potential level.109 This mimicry 
suggests that the pharmacophore queries created from PPI 
complex structures can be used to identify SMPPII via  virtual 
screening.110 Different methods can be employed to map the 
pharmacophore features onto the amino acids present at 
the PPI interface.111 Several SMPPII discoveries have been 
achieved, thanks to pharmacophore searches using manually 
created search features,112,113 or a consensus of interactions 
at the PPI interface,114,115 or using automated methods,116 
or by identification of the key interactions using molecular 
interaction field analysis.69
PPIs are especially promising targets for controlling 
inappropriate signaling, as found in diseases such as cancer. 
The usefulness of pharmacophore modeling to create queries 
encoding the key interactions at the PPI interface will prob-
ably strongly stimulate the discovery of novel SMPPII using 
pharmacophores, both as a stand-alone virtual screening tool 
and incorporated into pipelines with other methods.
A potential role in protein design?
Although pharmacophore modeling originated as a drug 
design concept and, as indicated earlier, is nowadays a key 
element of CADD, pharmacophore modeling shows promise 
in the currently burgeoning field of computational protein 
design.117 Rather than designing drugs for a given protein 
target, the aim in computational protein design is to derive an 
amino acid sequence that will fold into a given structure with 
a desired function. In many cases, this may involve protein–
small molecule ligand interactions,118 and for these it can 
easily be imagined that pharmacophores may be used simply 
by reversing the process of small molecule drug design for a 
known protein structure.
First of all, suitable protein templates (enzymes or 
 otherwise) should be identified for the protein redesign 
 process. The ligand of interest could serve as a query to try 
to identify possible binding proteins, which can then later be 
redesigned to give optimum complementarity to the ligand. 
Second, during the virtual protein design process, often 
multiple rotamers of different amino acids are sampled to 
identify the most desirable ones.119 Similar to ligand fitting 
with a pharmacophore query, the protein side chains can be 
fitted to features describing the complementary interactions 
required at the protein–ligand interface.
Conclusion
The pharmacophore concept was first put forward as a useful 
picture of drug interactions almost a century ago, and with 
the rise in computational power over the last few decades, 
has become a well-established CADD method with numer-
ous different applications in drug discovery. Depending on 
the prior knowledge of the system, pharmacophores can be 
used to identify derivatives of compounds, change the scaf-
fold to new compounds with a similar target, virtual screen 
for novel inhibitors, profile compounds for ADME-tox, 
investigate possible off-targets, or just complement other 
molecular methods. While there are limitations to the phar-
macophore concept, multiple remedies are available at any 
time to counter them. Given this versatility, it is expected that 
pharmacophore modeling will maintain a dominant role in 
CADD for the foreseeable future, and any medicinal chemist 
should be aware of its benefits and possibilities.
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